Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $65.
January 31, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating on Rocket Pharmaceuticals with a steady price target of $65.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst like Louise Chen could lead to increased investor confidence in Rocket Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100